The Role of Immunotherapies in Upper GI Cancers


Expert perspectives on the role of immunotherapies in upper gastrointestinal cancers, highlighting the CheckMate 649 study investigating frontline nivolumab plus chemotherapy.

Case: A 60-Year-Old Man with Stage IV Gastric Adenocarcinoma

Clinical Presentation:

  • A 60-year-old man with abrupt 10-pound weight loss, dyspepsia, bloating after meals, and loss of appetite, and all symptoms worsening over the past three months.
  • PMH and FHx: Overweight and HTN. Patients father deceased at age 50 due to gastric cancer.

Initial Clinical Workup and Diagnosis:

  • EGD showed 2 cm protruding mass in the body of the stomach
    • No Ulcerations
    • Biopsy showed poorly differentiated adenocarcinoma
  • Stage IV adenocarcinoma
  • Molecular Testing: HER2/neu –; MMRp/MSS, PD-L1 CPS 5%
  • CT of abdomen and chest reveal a gastric polypoid mass and thickening; No ascites; 2 lesions in the left lower lobe.
  • Lung Biopsy: metastatic adenocarcinoma consistent with gastric primary
  • PET/CT confirmed metastatic disease

Current Treatments:

  • Patient was initiated on FOLFOX +nivolumab
Related Videos
Related Content